Clinical Trial Update: A Trial of AK104 Plus Anlotinib in NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicating completion of Phase 1 and Phase 2 studies of AK104 plus anlotinib in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Anlotinib (anlotinib)

Snippet

Sponsor: Akeso | Conditions: NSCLC | Phase 1, Phase 2 | Status: COMPLETED